CLSD Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 10:00):

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space...

Stats
Today's Volume	42 867.00
Average Volume	370 043
Market Cap	99.38M
EPS	$0 ( 2024-03-12 )
Next earnings date	( $-0.140 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.51
ATR14	$0.0170 (1.28%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-18	Gibney Anthony S	Buy	93 290	Common Stock
2024-04-17	Gibney Anthony S	Buy	6 710	Common Stock
2024-04-15	Gibney Anthony S	Buy	45 000	Stock Option (right to buy)
2024-04-15	Gibney Anthony S	Buy	0
2024-03-20	Chong Ngai Hang Victor	Buy	30 000	Common Stock

INSIDER POWER
66.43
Last 97 transactions
Buy: 5 495 368 \| Sell: 2 175 231

Volume Correlation

Long: -0.08 (neutral)

Short: 0.40 (neutral)

Signal:(61.018) Neutral

Clearside Biomedical Inc Correlation

10 Most Positive Correlations
BNIXU	0.821
HOTH	0.802

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Clearside Biomedical Inc Correlation - Currency/Commodity

0.46
( neutral )

0.14
( neutral )

0.00
( neutral )

0.42
( neutral )

0.00
( neutral )

-0.44
( neutral )

Clearside Biomedical Inc Financials

Annual	2023
Revenue:	$8.23M
Gross Profit:	$7.80M (94.87 %)
EPS:	$-0.530

FY	2023
Revenue:	$8.23M
Gross Profit:	$7.80M (94.87 %)
EPS:	$-0.530

FY	2022
Revenue:	$1.33M
Gross Profit:	$1.12M (84.63 %)
EPS:	$-0.570

FY	2021
Revenue:	$29.58M
Gross Profit:	$29.58M (100.00 %)
EPS:	$0.00632

Financial Reports:

No articles found.

Clearside Biomedical Inc

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.